AMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) EV/FCF
As of 5 November 2026, AMNEAL PHARMACEUTICALS, INC. (AMRX) trades at a EV/FCF of −158×. Over the past ten years it has ranged from −783× (September 2026) to 119× (August 2020); the current reading is higher than 9% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 27.3× | 23.20% |
| FY2024 | 22.1× | 70.17% |
| FY2023 | 13.0× | (79.60%) |
| FY2022 | 63.8× | 784.00% |
| FY2021 | 7.2× | (29.56%) |
| FY2020 | 10.2× | — |
| FY2019 | −33.2× | — |
| FY2018 | 23.5× | 26.16% |
| FY2017 | 18.6× | 0.00% |
| FY2016 | 18.6× | 0.00% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −162× | — |
| Jun 2026 | −695× | — |
| Mar 2026 | 33.5× | 22.84% |
| Dec 2025 | 27.3× | 18.31% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. | −158× |
| LNTH Lantheus Holdings, Inc. compare | 16.6× |
| LQDA Liquidia Corporation compare | 25.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 32.2× |
| ALKS Alkermes plc compare | 36.0× |
| ELAN Elanco Animal Health Incorporated compare | 42.7× |
| HIMS Hims & Hers Health, Inc. compare | 73.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
| SUPN Indivior Pharmaceuticals Inc. compare | 138× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement